Synonyms: ALKS-33 | ALKS33 | compound 5 [PMID:15808478] | Lybalvi® (olanzapine + samidorphan)
samidorphan is an approved drug (FDA (2021))
Compound class:
Synthetic organic
Comment: Samidorphan (ALKS-33) is a novel μ-opioid receptor antagonist that was developed by Alkermes [1]. Structurally it is a naltrexone analogue. The intention was for samidorphan to be used in combination with the atypical antipsychotic olanzapine (in a formulation known as Lybalvi®, ALKS-3831, or the abbreviation OLZ/SAM) as a therapy for schizophrenia and bipolar disorder. Addition of samidorphan was proposed to mitigate olanzapine-induced weight gain.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM. (2005)
Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett, 15 (8): 2107-10. [PMID:15808478] |